+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
ID04977076

Safety Study of Continuing Versus Interrupting Direct Oral Anticoagulants DOAC in Adults Undergoing Elective Coronary Angiography or Percutaneous Coronary Intervention

Led by Zuyderland Medisch Centrum · Updated on 2026-05-29

1270

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Patients with atrial fibrillation AF often also have coronary artery disease CAD, and many require coronary stenting. Direct Oral Anticoagulants DOAC are commonly used to prevent blood clots in AF patients, replacing older Vitamin-K Antagonists. This trial investigates the safety of continuing DOAC treatment without interruption during elective invasive coronary angiography ICA or percutaneous coronary intervention PCI, as current guidelines recommend stopping DOACs 24-48 hours before these procedures but are based on limited evidence. The study is a prospective, multicenter, randomized trial focused on assessing bleeding risks related to uninterrupted DOAC use.

CONDITIONS

Brief Title

Comparison Between Direct Oral Anticoagulation (DOAC) Interruption and DOAC Continuation in Patients Undergoing Elective Invasive Coronary Angiography or Percutaneous Coronary Intervention

Research Team

S

Sanne Janssen, MSC

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here